J&J's Darzalex makes FDA history with another myeloma nod in new patients

Johnson & Johnson’s multiple myeloma drug Darzalex has another FDA nod in previously untreated patients under its belt—and this time it has become the first biologic regimen for those who are eligible for transplant.